Literature DB >> 18629643

Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody.

Takashi Himoto1, Seiji Nakai, Fumihiko Kinekawa, Hirohito Yoneyama, Akihiro Deguchi, Kazutaka Kurokochi, Tsutomu Masaki, Shoichi Senda, Reiji Haba, Seishiro Watanabe, Mikio Nishioka, Shigeki Kuriyama.   

Abstract

The association between anticentromere antibody (ACA) and hepatitis C virus (HCV) infection remains unclear. We subjected eight patients with HCV-related chronic liver disease (CLD) seropositive for ACA to a battery of clinical and laboratory tests. The patient cohort was dominated by females, and four of the eight (50%) patients had a concomitant autoimmune disease. All of the patients had high titers of ACA (>or=1:320). The histological activity index scores in chronic hepatitis C (CH-C) patients with ACA were significantly higher than those in CH-C patients without antinuclear antibody (ANA) (12.8 +/- 1.8 vs. 8.3 +/- 4.5, P = 0.0372). The frequency of human leukocyte antigen (HLA) DR-8 in patients with HCV-related CLD seropositive for ACA was significantly higher than that in patients with CH-C seronegative for ANA (71 vs. 18%, P = 0.0108). These findings suggest that ACA is induced by chronic HCV infection in association with HLA DR-8, and that CH-C patients with ACA exhibit more severe hepatic fibrosis and inflammation than CH-C patients without ANA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18629643     DOI: 10.1007/s10620-008-0359-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  53 in total

1.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

Review 2.  Autoimmunity and extrahepatic manifestations in hepatitis C virus infection.

Authors:  M P Manns; E G Rambusch
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

3.  Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies.

Authors:  W Earnshaw; B Bordwell; C Marino; N Rothfield
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

5.  Expression and clinical significance of antinuclear antibody in hepatitis C virus infection.

Authors:  Y C Peng; S C Hsieh; D Y Yang; C F Tung; W H Hu; W N Huang; G H Chen
Journal:  J Clin Gastroenterol       Date:  2001 Nov-Dec       Impact factor: 3.062

6.  Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis.

Authors:  M W Fried; J O Draguesku; M Shindo; L H Simpson; S M Banks; J H Hoofnagle; A M Di Bisceglie
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

7.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

8.  Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals.

Authors:  M Hashimoto; T Kinoshita; M Yamasaki; H Tanaka; T Imanishi; H Ihara; Y Ichikawa; T Fukunishi
Journal:  Tissue Antigens       Date:  1994-09

9.  Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.

Authors:  M-Y Hsieh; C-Y Dai; L-P Lee; J-F Huang; W-C Tsai; N-J Hou; Z-Y Lin; S-C Chen; L-Y Wang; W-Y Chang; W-L Chuang; M-L Yu
Journal:  J Clin Pathol       Date:  2007-06-01       Impact factor: 3.411

10.  Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort.

Authors:  M Lenzi; S Bellentani; G Saccoccio; P Muratori; F Masutti; L Muratori; F Cassani; F B Bianchi; C Tiribelli
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

View more
  6 in total

1.  Clinical significance of autoantibodies to p53 protein in patients with autoimmune liver diseases.

Authors:  Takashi Himoto; Hirohito Yoneyama; Kazutaka Kurokohchi; Michio Inukai; Hisashi Masugata; Fuminori Goda; Reiji Haba; Seishiro Watanabe; Shoichi Senda; Tsutomu Masaki
Journal:  Can J Gastroenterol       Date:  2012-03       Impact factor: 3.522

Review 2.  Autoantibodies as prognostic markers in autoimmune liver disease.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-05-13       Impact factor: 3.199

Review 3.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Clinical relevance of antibodies to cardiolipin in patients with chronic hepatitis C.

Authors:  Takashi Himoto; Hirohito Yoneyama; Kazutaka Kurokohchi; Hirohito Mori; Michio Inukai; Hisashi Masugata; Fuminori Goda; Reiji Haba; Seishiro Watanabe; Shoich Senda; Tsutomu Masaki
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

Review 5.  Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Authors:  Takashi Himoto; Mikio Nishioka
Journal:  Auto Immun Highlights       Date:  2013-02-22

Review 6.  Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection.

Authors:  Takashi Himoto; Tsutomu Masaki
Journal:  Clin Dev Immunol       Date:  2012-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.